Lv4
526 积分 2024-11-11 加入
Interventions to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
3个月前
已完结
Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia
3个月前
已完结
Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model
3个月前
已关闭
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial
4个月前
已完结
Leveraging Model-Informed Drug Development to Predict Asciminib Efficacy in Second-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase
4个月前
已完结
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial
4个月前
已完结
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
4个月前
已完结
Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1
5个月前
已关闭
Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1
5个月前
已完结
Predicting Drug-Drug Interactions Involving Rifampicin Using a Semi-mechanistic Hepatic Compartmental Model
8个月前
已完结
皖公网安备34019202002308
